Loxo Oncology (NASDAQ:LOXO) VP Jennifer Burstein sold 1,700 shares of Loxo Oncology stock in a transaction that occurred on Tuesday, April 24th. The shares were sold at an average price of $131.65, for a total value of $223,805.00. Following the completion of the sale, the vice president now owns 1,700 shares in the company, valued at $223,805. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Jennifer Burstein also recently made the following trade(s):

  • On Tuesday, March 13th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The shares were sold at an average price of $131.33, for a total value of $223,261.00.
  • On Monday, February 12th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The shares were sold at an average price of $93.24, for a total value of $158,508.00.

Shares of LOXO stock opened at $129.40 on Friday. Loxo Oncology has a 1 year low of $42.11 and a 1 year high of $138.54.

Loxo Oncology (NASDAQ:LOXO) last issued its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.53. The firm had revenue of $21.30 million for the quarter. research analysts predict that Loxo Oncology will post 0.3 earnings per share for the current fiscal year.

Hedge funds have recently modified their holdings of the stock. Cambridge Investment Research Advisors Inc. raised its holdings in Loxo Oncology by 26.8% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 2,917 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 617 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Loxo Oncology during the fourth quarter worth $323,000. Sands Capital Management LLC acquired a new position in Loxo Oncology during the fourth quarter worth $191,266,000. Pinnacle Associates Ltd. acquired a new position in Loxo Oncology during the fourth quarter worth $451,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Loxo Oncology by 12.0% in the third quarter. Wells Fargo & Company MN now owns 18,028 shares of the biopharmaceutical company’s stock worth $1,661,000 after acquiring an additional 1,933 shares during the last quarter.

A number of analysts recently weighed in on LOXO shares. BidaskClub upgraded Loxo Oncology from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Zacks Investment Research upgraded Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Morgan Stanley downgraded Loxo Oncology from an “overweight” rating to an “equal weight” rating and set a $103.00 price target on the stock. in a research note on Wednesday, March 21st. They noted that the move was a valuation call. CIBC started coverage on Loxo Oncology in a research note on Thursday, February 22nd. They issued an “outperform” rating and a $132.00 price target on the stock. Finally, ValuEngine upgraded Loxo Oncology from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. One investment analyst has rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $131.89.

Loxo Oncology Company Profile

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.